OrbiMed Capital GP VII LLC
SEC CIK 1760648 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| PASG | Passage BIO, Inc. | 10% | 6.89M | $4.76M | $515.3K | 9 | 2022-01-11 | 2025-04-15 |
| ELVN | Enliven Therapeutics, Inc. | Dir, 10% | 7.66M | $20.00M | $22.88M | 4 | 2021-07-16 | 2024-05-16 |
| DMRA | Damora Therapeutics, Inc. | 10% | 2.11M | — | $742.7K | 2 | 2023-07-25 | 2023-07-31 |
| ARQT | Arcutis Biotherapeutics, Inc. | 10% | 3.53M | — | $7.29M | 1 | 2022-06-24 | 2022-06-24 |
Most active insiders at PASG, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Lynx1 Capital Management LP | 10% | $206.1K | — |
| 2 | Chou William | Pres AND CEO, Dir | — | $75.2K |
| 3 | Borthwick Kathleen | CFO | — | $38.0K |
OrbiMed Capital GP VII LLC made no open-market trades at PASG in the last 12 months.
Transactions 16
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2025-04-17 | 2025-04-15+ | PASG | Passage BIO, Inc. | OrbiMed Capital GP VII LLC | 10% | S - Sale | $0.3335 | -149.1K | 6.89M | -2% | -$49.7K |
| MI | 2025-01-08 | 2025-01-06+ | PASG | Passage BIO, Inc. | OrbiMed Capital GP VII LLC | 10% | S - Sale | $0.7026 | -147.0K | 7.26M | -2% | -$103.3K |
| I | 2024-12-26 | 2024-12-20 | PASG | Passage BIO, Inc. | OrbiMed Capital GP VII LLC | 10% | S - Sale | $0.6 | -230.3K | 7.40M | -3% | -$138.2K |
| MI | 2024-12-06 | 2024-12-04+ | PASG | Passage BIO, Inc. | OrbiMed Capital GP VII LLC | 10% | S - Sale | $0.7965 | -97.1K | 7.70M | -1% | -$77.3K |
| MI | 2024-09-18 | 2024-09-16+ | PASG | Passage BIO, Inc. | OrbiMed Capital GP VII LLC | 10% | S - Sale | $0.7332 | -200.1K | 7.86M | -2% | -$146.7K |
| MI | 2024-05-20 | 2024-05-16 | ELVN | Enliven Therapeutics, Inc. | OrbiMed Capital GP VII LLC | Dir, 10% | S - Sale | $22.14 | -1.03M | 7.66M | -12% | -$22.88M |
| MI | 2023-08-02 | 2023-07-31 | DMRA | Damora Therapeutics, Inc. | OrbiMed Capital GP VII LLC | 10% | S - Sale | $3.00 | -209.4K | 2.11M | -9% | -$628.2K |
| MI | 2023-07-27 | 2023-07-25 | DMRA | Damora Therapeutics, Inc. | OrbiMed Capital GP VII LLC | 10% | S - Sale | $2.92 | -39.2K | 909.6K | -4% | -$114.5K |
| DI | 2023-05-19 | 2023-05-17 | ELVN | Enliven Therapeutics, Inc. | OrbiMed Capital GP VII LLC | Dir, 10% | M - OptEx | $4.28 | +2,125 | 8.66M | +0.0% | +$9,095 |
| MI | 2022-06-28 | 2022-06-24 | ARQT | Arcutis Biotherapeutics, Inc. | OrbiMed Capital GP VII LLC | 10% | S - Sale | $21.31 | -342.0K | 3.53M | -9% | -$7.29M |
| MI | 2022-05-05 | 2022-05-03+ | PASG | Passage BIO, Inc. | OrbiMed Capital GP VII LLC | 10% | P - Purchase | $1.94 | +525.0K | 6.84M | +8% | +$1.02M |
| I | 2022-01-24 | 2022-01-20 | PASG | Passage BIO, Inc. | OrbiMed Capital GP VII LLC | 10% | P - Purchase | $5.42 | +369.1K | 6.63M | +6% | +$2.00M |
| MI | 2022-01-20 | 2022-01-14+ | PASG | Passage BIO, Inc. | OrbiMed Capital GP VII LLC | 10% | P - Purchase | $5.38 | +168.3K | 6.27M | +3% | +$905.2K |
| MI | 2022-01-13 | 2022-01-11+ | PASG | Passage BIO, Inc. | OrbiMed Capital GP VII LLC | 10% | P - Purchase | $5.61 | +150.0K | 6.06M | +3% | +$841.1K |
| AI | 2021-07-23 | 2021-07-16 | ELVN | Enliven Therapeutics, Inc. | OrbiMed Capital GP VII LLC | Dir, 10% | P - Purchase | $6.00 | +1.67M | 4.20M | +66% | +$10.00M |
| I | 2021-07-16 | 2021-07-16 | ELVN | Enliven Therapeutics, Inc. | OrbiMed Capital GP VII LLC | Dir, 10% | P - Purchase | $6.00 | +1.67M | 1.67M | New | +$10.00M |
Purchase Sale Sale after option exercise All abbreviations